ArticleSchizophrenia bulletin open2021
Progressive Changes in Glutamate Concentration in Early Stages of Schizophrenia: A Longitudinal 7-Tesla MRS Study.
Article in Schizophrenia bulletin open, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Pooled it
- The trajectory of putative astroglial dysfunction in first episode schizophrenia: a longitudinal 7-Tesla MRS study.Scientific reports · 2021Trial
- Development and in vivo proof-of-concept of delayed alternating nutation tailored excitation point resolved spectroscopy (dante-press): a frequency-selective single voxel spectroscopy sequence applied to in vivo measurements of naa and glu at 7.0 T.Magma (New York, N.Y.) · 2026Article
- Aging in Schizophrenia: Perspectives on Molecular Mechanisms and a Mini-review.Schizophrenia bulletin · 2026Review
- Cerebral glutamate levels over two years in initially antipsychotic-naïve first-episode patients with psychosis are related to clinical symptoms and cognition.Molecular psychiatry · 2025Article
- Glutamate, NAA, and energy metabolism in clinical high risk and first episode psychosis.Scientific reports · 2025Article
- Glutamate, Contextual Insensitivity, and Disorganized Speech in First-Episode Schizophrenia: A 7T Magnetic Resonance Spectroscopy Study.Biological psychiatry global open science · 2025Article
- Changes in glutamate levels in anterior cingulate cortex following 16 weeks of antipsychotic treatment in antipsychotic-naïve first-episode psychosis patients.Psychological medicine · 2025Article
- Neuronal Synaptic Communication and Mitochondrial Energetics in Human Health and Disease.Advances in experimental medicine and biology · 2025Review
- Leveraging ultra-high field (7T) MRI in psychiatric research.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024Review
- The impact of spectral basis set composition on estimated levels of cingulate glutamate and its associations with different personality traits.BMC psychiatry · 2024Article
- Longitudinal trajectories of anterior cingulate glutamate and subclinical psychotic experiences in early adolescence: the impact of bullying victimization.Molecular psychiatry · 2024Article
- Glutamatergic basis of antipsychotic response in first-episode psychosis: a dual voxel study of the anterior cingulate cortex.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024Article
- Dopamine Synthesis Capacity and GABA and Glutamate Levels Separate Antipsychotic-Naïve Patients With First-Episode Psychosis From Healthy Control Subjects in a Multimodal Prediction Model.Biological psychiatry global open science · 2023Article
- Multinuclear Magnetic Resonance Spectroscopy at Ultra-High-Field: Assessing Human Cerebral Metabolism in Healthy and Diseased States.Metabolites · 2023Review
- Anterior cingulate glutamate metabolites as a predictor of antipsychotic response in first episode psychosis: data from the STRATA collaboration.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2023Article
- Glutamatergic dysfunction in Schizophrenia.Translational psychiatry · 2022Review
- Computational Modeling of Electroencephalography and Functional Magnetic Resonance Imaging Paradigms Indicates a Consistent Loss of Pyramidal Cell Synaptic Gain in Schizophrenia.Biological psychiatry · 2022Article
- Widespread cortical thinning, excessive glutamate and impaired linguistic functioning in schizophrenia: A cluster analytic approach.Frontiers in human neuroscience · 2022Article
- Ultra-high field neuroimaging in psychosis: A narrative review.Frontiers in psychiatry · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Progressive reduction in glutamatergic transmission has been proposed as an important component of the illness trajectory of schizophrenia. Despite its popularity, to date, this notion has not been convincingly tested in patients in early stages of schizophrenia. In a longitudinal 7T magnetic resonance spectroscopy (1H-MRS), we quantified glutamate at the dorsal anterior cingulate cortex in 21 participants with a median lifetime antipsychotic exposure of less than 3 days and followed them up after 6 months of treatment. Ten healthy controls were also scanned at 2 time points. While patients had significantly lower overall glutamate levels than healthy controls (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.